Journal profile · Agricultural and Biological Sciences-Animal Science and Zoology
Current Research in Pharmacology and Drug Discovery
ISSN 2590-2571 · Elsevier · Netherlands
Current Research in Pharmacology and Drug Discovery: fully open access; APC about USD 3,280; median 138 days to acceptance (41 articles, last 24 months); 35 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Current Research in Pharmacology and Drug Discovery is published by Elsevier. By OpenAlex counts of its recent articles, its largest topics are SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies and Computational Drug Discovery Methods, together about 24.2% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Current Research in Pharmacology and Drug Discovery (CRPHAR) is a new primary research, gold open access journal from Elsevier. CRPHAR publishes original papers, reviews, graphical reviews, short communications and follow-up manuscripts resulting from research in pharmacology and drug discovery that cover aspects of drug action at the cellular, molecular, and biochemical level.Current Research in Pharmacology and Drug Discovery is a peer-reviewed gold open access (OA) journal and upon acceptance all articles are permanently and freely available. It is a companion to the highly regarded review journal Current Opinion in Pharmacology (2020 Journal Impact Factor 5.547, CiteScore 9.3) and is part of the Current Opinion and Research (CO+RE) suite of journals . All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists' workflow.Current Research in Pharmacology and Drug Discovery topics covered include neuropharmacology (psychiatry and neurodegeneration); sensory pharmacology (ocular, auditory and pain); cardiovascular; renal; respiratory; musculoskeletal; cancer; immunopharmacology (inflammation and innate immune system function); anti-infectives; gastrointestinal; endocrine; metabolic; systems pharmacology and signalling; drug metabolism; pharmaceutics and drug delivery; pharmacogenetics; analytical toxicology; pharmacokinetics; new technologies; and translational and clinical pharmacology.Current Research in Pharmacology and Drug Discovery builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health.Expertise - Editors and Editorial Board bring depth and breadth of expertise and experience to the journal.Speed - Submission and peer review is fast, and publication of final manuscripts is instantaneous.Discoverability - Articles get high visibility and maximum exposure on an industry-leading platform that reaches a vast global audience.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. For more information, please refer to: https://www.elsevier.com/conflictsofinterest
From the journal's Aims & Scope
Research area (LetPub): Agricultural and Biological Sciences-Animal Science and Zoology
Editor-in-chief Luigino CalzettaPublisher website
Editorial board by country: 5 in mainland China (about 14%); most named Italy 11, United States 7, Mainland China 5, United Kingdom 2, India 2 (35 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- SARS-CoV-2 and COVID-19 ResearchMedicine8.4%
- COVID-19 Clinical Research StudiesMedicine7.9%
- Computational Drug Discovery MethodsComputer Science7.9%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics6.5%
- Inflammatory Bowel DiseaseBiochemistry, Genetics and Molecular Biology5.1%
- Asthma and respiratory diseasesMedicine4.2%
- Nanoparticle-Based Drug DeliveryMaterials Science4.2%
- Alzheimer's disease research and treatmentsMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Animal Science and Zoology | Q1 | 8/520 | 98th |
| Ecology, Evolution, Behavior and Systematics | Q1 | 24/736 | 96th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2020
- 5.55Publisher website ·
- CiteScore 2026-06
- 11.4LetPub ·
- CiteScore (publisher)
- 11.4Publisher website ·
- SJR 2026-06
- 1.39LetPub ·
- SNIP 2026-06
- 1.7LetPub ·
- h-index
- 34OpenAlex ·
- i10-index
- 117OpenAlex ·
- 2-year mean citedness
- 6.94OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 247 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 11 | 11 | 1,058 |
| 2025 | 35 | 35 | 1,150 |
| 2024 | 33 | 33 | 924 |
| 2023 | 16 | 16 | 715 |
| 2022 | 71 | 71 | 456 |
| 2021 | 66 | 66 | 77 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
138 daysMedian, submission to acceptance · P25–P75 85 days – 164 days
- Acceptance to online
- median 3 days (41 articles)
- Submission to online
- median 141 days
- Sample
- 41 articles with submission and acceptance dates (43 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 10 weeksLetPub ·
- Submission to first decision
- 12 daysPublisher website ·
- First decision after review
- 59 daysPublisher website ·
- Submission to acceptance
- 113 daysPublisher website ·
- Acceptance to publication
- 3 daysPublisher website ·
- Submission to publication (journal-reported)
- about 18 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,280 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,680 / EUR 2,510 / GBP 2,150 / JPY 332,400 | — | — | |
| LetPub | USD 2,500 | Yes | — | |
| Publisher website | USD 3,680 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- Numbered, in order of citation
- First submission
- Free format: the journal's layout is not required
- Highlights
- Required
- Graphical abstract
- Required
Article types accepted9
- graphical reviewsThe Journal publishes Research Papers, Short Communications and Graphical Reviews.Length not stated
- hypothesisThe Journal publishes Research Papers, Short Communications and Graphical Reviews. We support the "Your Paper Your Way" Elsevier guideline which allows authors …Length not stated
- meta-analysisThe Journal publishes Research Papers, Short Communications and Graphical Reviews. We support the "Your Paper Your Way" Elsevier guideline which allows authors …Length not stated
- research paperThe Journal publishes Research Papers, Short Communications and Graphical Reviews. We support the "Your Paper Your Way" Elsevier guideline which allows authors …Length not stated
- research papersThe Journal publishes Research Papers, Short Communications and Graphical Reviews.Length not stated
- reviewThe Journal publishes Research Papers, Short Communications and Graphical Reviews. We support the "Your Paper Your Way" Elsevier guideline which allows authors …Length not stated
- review articleReview Article Before submitting a review, you are encouraged to present a pre-submission proposal to the Editorial office (crphar-me@elsevier.com) for approval…Length not stated
- short communicationThe Journal publishes Research Papers, Short Communications and Graphical Reviews. We support the "Your Paper Your Way" Elsevier guideline which allows authors …Length not stated
- short communicationsThe Journal publishes Research Papers, Short Communications and Graphical Reviews.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Follow Elsevier's Publishing Ethics Policy Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed, does not count as prior publication Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- Netherlands
- Language
- English
- ISSN
- 2590-2571
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Current Research in Pharmacology and Drug Discovery
How long does peer review take at Current Research in Pharmacology and Drug Discovery?
Based on the dates recorded on 41 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 138 days (interquartile range 85–164 days); authors report an average review time of about 10 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Current Research in Pharmacology and Drug Discovery?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: Numbered, in order of citation; First submission: Free format: the journal's layout is not required; Highlights: Required; Graphical abstract: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Current Research in Pharmacology and Drug Discovery based?
Of the 35 board members whose country the journal's board page names, 5 (about 14%) are in mainland China; the countries named most often are Italy (11), United States (7) and Mainland China (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Current Research in Pharmacology and Drug Discovery?
According to LetPub and DOAJ records, Current Research in Pharmacology and Drug Discovery is indexed in Scopus and DOAJ.
Is Current Research in Pharmacology and Drug Discovery open access, and what is the APC?
Current Research in Pharmacology and Drug Discovery is a fully open-access journal. APC about USD 3,280.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .